NYSE:HQL abrdn Life Sciences Investors (HQL) Stock Price, News & Analysis $19.26 -0.13 (-0.69%) Closing price 03:59 PM EasternExtended Trading$19.50 +0.24 (+1.27%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsDividendInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About abrdn Life Sciences Investors Stock (NYSE:HQL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get HQL alerts:Sign Up Key Stats Today's Range$19.16▼$19.5650-Day Range$19.14▼$22.6452-Week Range$13.90▼$22.67Volume158,948 shsAverage Volume139,687 shsMarket Capitalization$585.57 millionP/E RatioN/ADividend Yield11.63%Price TargetN/AConsensus RatingN/A Company Overview abrdn Life Sciences Investors (NYSE:HQL) is a non-diversified, closed-end investment company focused on the global life sciences sector. The fund seeks long-term capital appreciation by investing in companies involved in biotechnology, pharmaceuticals, medical devices, healthcare services and other related industries. The fund may invest in both publicly traded and privately held companies across various stages of development, including businesses developing innovative therapies, diagnostic technologies and other healthcare products. Its portfolio can include companies based in the United States and other international markets, providing exposure to the broader global life sciences industry. abrdn Life Sciences Investors was previously known as Tekla Life Sciences Investors before adopting its current name following the transition of its investment management platform to abrdn. The fund is managed by abrdn, a global investment company that provides asset management services to institutional and individual investors.AI Generated. May Contain Errors. Read More Receive HQL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for abrdn Life Sciences Investors and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HQL Stock News HeadlinesHQL: The Rally That Makes Growth Harder (Rating Downgrade)September 15 at 7:00 AM | seekingalpha.comabrdn Life Sciences Investors Q2 2026 CommentaryAugust 13, 2026 | seekingalpha.comIran War: Why Is Trump Protecting THEM?A powerful Middle Eastern government is reportedly seeking US intelligence, targeting help, and military protection against Iran-backed forces. An anonymous source says that protection was only one side of an extraordinary bargain, with the other side potentially worth trillions of dollars to America. Addison Wiggin traced the deal linking Trump, Iran, and this government, and says the headlines look very different once you know who is involved.September 16 at 1:00 AM | Banyan Hill Publishing (Ad)abrdn Life Sciences Investors Q1 2026 CommentaryMay 20, 2026 | seekingalpha.comHQL: Attractive Outlook With Growth Of GLP-1 MarketMay 19, 2026 | seekingalpha.comabrdn Life Sciences Investors declares $0.56 dividendMay 12, 2026 | seekingalpha.comCertain Aberdeen Investments U.S. Closed-End Funds Declare Distribution Dates and AmountsMay 11, 2026 | prnewswire.comAbrdn Life Sciences Investors Fund Q4 2025 CommentaryFebruary 25, 2026 | seekingalpha.comSee More Headlines HQL Stock Analysis - Frequently Asked Questions How have HQL shares performed this year? abrdn Life Sciences Investors' stock was trading at $16.79 at the beginning of 2026. Since then, HQL stock has increased by 14.7% and is now trading at $19.2560. Who are abrdn Life Sciences Investors' major shareholders? abrdn Life Sciences Investors' top institutional shareholders include 180 Wealth Advisors LLC (0.50%), Rivernorth Capital Management LLC (0.49%), 1607 Capital Partners LLC (0.25%) and KPP Advisory Services LLC (0.08%). Insiders that own company stock include Saba Capital Management, LP, Daniel R Omstead, Kathleen Goetz, Todd Reit and Rose Dimartino. View institutional ownership trends. How do I buy shares of abrdn Life Sciences Investors? Shares of HQL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of abrdn Life Sciences Investors own? Based on aggregate information from My MarketBeat watchlists, some other companies that abrdn Life Sciences Investors investors own include Rithm Capital (RITM), DoubleLine Income Solutions Fund (DSL), Verizon Communications (VZ), International Business Machines (IBM), Eaton Vance Tax-Managed Global Diversified Equity Income Fund (EXG) and Energy Transfer (ET). Company Calendar Record date for 9/30 Dividend8/24/2026Ex-Dividend for 9/30 Dividend8/24/2026Record date for 8/31 Dividend8/24/2026Ex-Dividend for 8/31 Dividend8/24/2026Dividend Payable8/31/2026Today9/16/2026Dividend Payable9/30/2026Fiscal Year End9/30/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (6d) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 6 days, HQL's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorFinance Industry Capital Markets Sub-IndustryN/A Current SymbolNYSE:HQL CIK884121 Webwww.abrdnhql.com Phone(617) 772-8500Fax617-772-8577EmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares30,410,000Free Float27,349,000Market Cap$585.57 million OptionableNot Optionable Beta0.76 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NYSE:HQL) was last updated on 9/16/2026 by MarketBeat.com Staff. From Our PartnersA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altuche...Paradigm Press | SponsoredGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...Golden Portfolio | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredTSM just handed Trump's secretive AI project $100 billion — See this before September 29Taiwan Semiconductor just pledged another $100 billion to US chip manufacturing, bringing its total US investm...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding abrdn Life Sciences Investors Please log in to your account or sign up in order to add this asset to your watchlist. Share abrdn Life Sciences Investors With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.